Contract analysis

1. Does T&K recommend pursuing a correlative/corresponding adjustment with Irish Revenue in respect of the $47.6 million U.S. settlement? If so, should PBI proceed by way of a unilateral request to Irish Revenue, or should PPC and PBI jointly pursue a bilateral MAP request under Article 25 of the U.S.-Ireland Treaty?

2. What is the impact, if any, of the settlement on PBI's Knowledge Development box claims for FY 2016–2020? Does the quantum of the settlement, or its characterization as a CSA cost-sharing adjustment versus a royalty rate adjustment (or a blend), affect the KDB computation?

3. Please confirm that no Irish withholding tax liability arises on any incremental royalty amounts that may be recognized as a result of the settlement, given the 0% treaty rate under the U.S.-Ireland Treaty.

4. Should PBI's Irish transfer pricing documentation be updated or supplemented in light of the settlement?

5. In T&K's assessment, is there a material risk that the U.S. settlement could trigger an independent Irish Revenue transfer pricing audit of PBI?

6. What amended filing obligations, if any, arise for PBI in respect of FY 2017–2020?

7. Please provide an estimate of T&K's fees for the analysis described above and for any required filings or submissions. For budgeting purposes, I note that T&K's fees to date on this matter are approximately €312,500. **IV. Timeline and Next Steps** As noted, PPC is expected to formally accept the settlement offer by March 22, 2024, and we anticipate that the Form 906 Closing Agreement will be executed by the end o